Abstract 1826: Obesity as a therapeutic target for preventing recurrence and mortality in prostate cancer survivors: A meta-analysis of 29 cohort studies

Abstract

Abstract Objective: The role of body mass index (BMI) remains unclear for disease recurrence and survival in patients with prostate cancer. To evaluated the role of BMI in prostate cancer survivors, we performed a meta-analysis for comparing biochemical recurrence-free survival (BCRFS), progression-free survival (PFS) and overall survival (OS) among normal weight (BMI <25 kg/m2), overweight (BMI 25 – 29.9 kg/m2) and obesity (BMI ≥30 kg/m2). Methods: After the extensive literature search till July 2010, we analyzed 29 relevant cohort studies where the role of BMI was investigated for BCRFS, PFS and OS in prostate cancer survivors. We used the fixed-effect model for the meta-analysis because of no observed heterogeneity among all relevant studies (Higgins I2 ≤50%). Results: Although there was no difference in BCRFS between BMI <25 kg/m2 and ≥25 kg/m2 (HR, 1.02, 95% CI, 0.98 to 1.09), BMI ≥30 kg/m2 showed poor BCRFS when compared with BMI <30 kg/m2 (HR, 1.56, 95% CI, 1.48 to 1.65). In sub-analyses for BCRFS, BMI 25 – 29.9 kg/m2 showed poor BCRFS, compared with BMI <25 kg/m2 (HR, 1.08; 95% CI, 1.03 to 1.14), and BMI ≥30 kg/m2 was also associated with poor BCRFS, compared with BMI 25 – 29.9 kg/m2 (HR, 1.20; 95% CI, 1.12 to 1.29). Furthermore, BMI ≥30 kg/m2 was related with PFS (HR, 1.65; 95% CI, 1.43 to 1.91) and OS (HR, 1.73; 95% CI, 1.63 to 1.97) when compared with BMI <30 kg/m2, whereas there were no differences in them between BMI <25 kg/m2 and ≥25 kg/m2 (PFS and OS; HR, 1.01 and 1.05; 95% CI, 0.85 to 1.20 and 0.88 to 1.26). In sub-analyses for PFS and OS, BMI ≥30 kg/m2 also decreased PFS (HR, 1.45; 95% CI, 1.23 to 1.71) and OS (HR, 1.49; 95% CI, 1.29 to 1.72) when compared with BMI 25 – 29.9 kg/m2 in spite of no differences in them between BMI <25 kg/m2 and BMI 25 – 29.9 kg/m2 (PFS and OS; HR, 1.05 and 0.99; 95% CI, 0.88 to 1.26 and 0.88 to 1.11). Finally, these meta-analytic results showed no publication bias among all relevant studies. Conclusion: These findings suggest that overweight (BMI 25 – 29.9 kg/m2) and obesity (BMI ≥30 kg/m2) may be associated with early biochemical recurrence, whereas obesity (BMI ≥30 kg/m2) may influence on clinical poor prognosis such as PFS and OS in prostate cancer survivors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1826. doi:10.1158/1538-7445.AM2011-1826